ASCO and the Conquer Cancer Foundation (CCF) continue to recognize the donors whose generous contributions are making the vision of CancerLinQ™ a reality. In this latest installment, ASCO and CCF recognize healthcare companies Bayer HealthCare Pharmaceuticals Inc. and AstraZeneca for their commitment to advancing science through collaboration. Their donations will help ensure that CancerLinQ can provide quality care to cancer patients.
Bayer HealthCare Pharmaceuticals Inc.
With oncology as a key area of focus for Bayer, the company continuously seeks to make a difference beyond its own efforts. Its support of CancerLinQ is inspired by its mission of enabling “Science for a Better Life.” Bayer is fascinated by the potential to combine clinical outcomes with other real-world data.
“Although we have made dramatic progress in cancer research over last several decades, limited access in analysis of real world data can make it challenging to utilize this information to improve quality of care in oncology,” said Svetlana Kobina, MD, PhD and Head of Global Medical Affairs, Oncology at Bayer HealthCare Pharmaceuticals Inc. Bayer’s vision is to successfully translate the science of cancer into therapies that advance the way oncologists treat and manage the disease, regardless of stage. Clinical information provided by CancerLinQ has the power to drive forward cancer care and improve decision-making.
“Instead of learning from only the three percent of cancer patients who participate in clinical trials, CancerLinQ will harness big data and allow oncologists to learn from almost every patient, offering opportunity to drive new clinical understanding,” said Dr. Kobina.
AstraZeneca understands that improving patient outcomes in cancer care requires a collaborative approach. Its dedication to scientific discovery and quality care motivated AstraZeneca to join in supporting CancerLinQ.
“Currently there are very few occasions to gain insight into what treatments are utilized outside of clinical trials and the ability to understand the patient experience in a transparent way. In the era of big data, CancerLinQ is a wonderful opportunity,” said Gregory Curt, Executive Director of External Scientific and Clinical Relations, U.S. Medical Affairs at AstraZeneca Oncology.
AstraZeneca is committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. The organization was impressed with CancerLinQ’s capabilities and the opportunity it presented to learn from the real world evidence that may lead to better paradigms for overall patient care.
“CancerLinQ will impact cancer care across the treatment continuum from prevention to screening, and continue through treatment, survivorship, and end of life. This will create an opportunity for earlier and more effective interventions,” said Curt.
CancerLinQ™ is supported in part through the Conquer Cancer Foundation of the American Society of Clinical Oncology, whose generous donors have helped make CancerLinQ possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Scientific Affairs, LLC; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.